SCHEMBL7968519

SCHEMBL7968519

Cc1cc(COCC(N)CN)nc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.45
CYP1A2 P05177 1/20 0.44
TACR1 P25103 4/20 0.41
PDE10A Q9Y233 3/20 0.40
NPFFR1 Q9GZQ6 1/20 0.40
NPFFR2 Q9Y5X5 1/20 0.40
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
NOS2 P35228 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968514 1.00 BACE1 (0.45) BACE1CYP1A2TACR1PDE10ANPFFR1
SCHEMBL25523802 0.79 KDM4E (0.50) BACE1CYP1A2PDE10AKDM4EALDH1A1
SCHEMBL7967311 0.76 CYP1A2 (0.55) BACE1CYP1A2PDE10ANPFFR1NPFFR2
SCHEMBL7967305 0.75 CYP1A2 (0.53) BACE1CYP1A2PDE10ANPFFR1NPFFR2
SCHEMBL25523858 0.75 CYP1A2 (0.46) BACE1CYP1A2PDE10ANPFFR1NPFFR2
SCHEMBL29082858 0.75 CYP1A2 (0.46) BACE1CYP1A2PDE10ANPFFR1NPFFR2
SCHEMBL25523803 0.75 CYP1A2 (0.46) BACE1CYP1A2PDE10ANPFFR1NPFFR2
SCHEMBL28585633 0.74 CYSLTR1 (0.57) BACE1CYP1A2PDE10AKDM4EALDH1A1
SCHEMBL3969032 0.71 CYP1A2 (0.60) BACE1CYP1A2PDE10ANPFFR1NPFFR2
SCHEMBL3396098 0.70 ALDH1A1 (0.49) BACE1CYP1A2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US disclosed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP disclosed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO disclosed